Protocol

SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Diseases

Brain Tumor : Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

This study is designed to treat all patients with newly diagnosed medulloblastoma including any variant. Therapy of medulloblastoma has been based only on extent of disease (clinical risk), however recent studies show that there are different types of medulloblastoma also known as molecular subgroups. These are identified using molecular markers found in these tumors. Different molecular sub-groups have been found to respond differently to treatment. The therapy the participant receives will be based on the tumor’s molecular sub-group (molecular risk) and the extent of disease (clinical risk group).

Innovations to contemporary medulloblastoma therapy include reduced dose cyclophosphamide, reduced dose radiation therapy for low risk medulloblastoma, and use of novel therapies targeted toward the specific molecular subgroups of the disease.

All participants will be treated with risk-adapted radiation therapy and adjuvant chemotherapy. Participants who have a lower risk of disease recurrence will be treated with lower doses of radiation therapy thereby decreasing exposure and potential severity of side effects. Some participants will get targeted therapy based on their specific biology (SHH) and others who have a higher risk of disease recurrence will be treated with novel agents in addition to standard treatment. Please see the graph below showing the stratification based on molecular and clinical risk:

SJMB12 protocol algorithm-figures

There are three parts to this study:


Objectives


Eligibility Criteria, among others, include:

Histological diagnosis of Medulloblastoma including any variant and posterior fossa PNET


Contact

Amar Gajjar, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: (901) 595-2544 or (901) 595-4599
FAX: (901) 595-6211

Or

Giles Robinson, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: (901) 595-4445 or (901) 595-4599
FAX: (901) 595-6211

Or

Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: (901) 595-2544
FAX: (901) 595-6211

For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.